Lab Med Online.  2020 Apr;10(2):109-115. 10.3343/lmo.2020.10.2.109.

Comparison of Mac-2 Binding Protein Glycosylation Isomer, Fibroscan, and Other Fibrosis Markers for Assessing Liver Cirrhosis in Patients with Chronic Hepatitis B Virus-mediated Hepatocellular Carcinoma

• Lee K
• Yoo IY
• Joh JW
• Kim JM
• Gwak GY
• Sinn DH
• Ha SY
• Kang ES
• Park HD

• KMID: 2512240
• DOI: http://doi.org/10.3343/lmo.2020.10.2.109

Abstract

Background
Liver cirrhosis is advanced stage of hepatic brosis caused by viral hepatitis. Mac-2 binding protein glycosylation isomer (M2BPGi) is a serum marker to diagnose and evaluate hepatic brosis progression. In this study, we evaluated the efficacy of serum M2BPGi to predict chronic hepatitis B (HBV)-mediated cirrhosis by liver biopsy.
Methods
M2BPGi cut-off index (COI) was evaluated from 312 patients with chronic HBV-mediated hepatocellular carcinoma and 105 healthy controls. Comparative analysis was performed with conventional hepatic brosis markers such as brosis index based on four factors (FIB-4), aspartate aminotransferase-to-platelet ratio index (APRI), and Fibroscan.
Results
Korean Study Group for Pathology of Digestive Diseases classified 165 (52%) patients with histological stage F4 liver cirrhosis. Comparison of cases with stage F4 cirrhosis and stage F3 septal brosis revealed significant difference between M2BPGi, platelet count, APRI, FIB-4, and Fibroscan prediction. M2BPGi 2+ (COI ≥3) was found to be 8% in patients with F4 cirrhosis and 1% in patients with F3 brosis. In multi-regression analysis, M2BPGi showed higher odds ratio than that of other serum markers while M2BPGi 2+ showed comparable odds ratio to Fibroscan F3 and F4 assessment.
Conclusions
In patients with chronic HBV-mediated hepatocellular carcinoma, M2BPGi was neither comprehensive nor as effective as Fibroscan in assessing liver cirrhosis and brosis progression.

Keyword

M2BPGi; Hepatocellular carcinoma; Liver cirrhosis

Figure

• 

  Fig. 1 Scatter plot of log10 (M2BPGi) vs. log10 (Fibroscan) kPa (A) in histological F3 grade of septal fibrosis and (B) in histologic F4 grade of cirrhosis. Spearman’s correlation coefficients are 0.371 (95% CI: 0.217-0.506) for F3 and 0.391 (95% CI: 0.250-0.517) for F4.

Reference

1. Adams LA. 2011; Biomarkers of liver fibrosis. J Gastroenterol Hepatol. 26:802–9. DOI: 10.1111/j.1440-1746.2010.06612.x. PMID: 21198831.

2. European Association for Study of Liver and Asociacion Latinoameri-cana para el Estudio del Higado. 2015; EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 63:237–64. DOI: 10.1016/j.jhep.2015.04.006. PMID: 25911335.

3. Kuno A, Ikehara Y, Tanaka Y, Ito K, Matsuda A, Sekiya S, et al. 2013; A serum "sweet-doughnut" protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis. Sci Rep. 3:1065. DOI: 10.1038/srep01065. PMID: 23323209. PMCID: PMC3545220.

4. Toshima T, Shirabe K, Ikegami T, Yoshizumi T, Kuno A, Togayachi A, et al. 2015; A novel serum marker, glycosylated Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA(+)-M2BP), for assessing liver brosis. J Gastroenterol. 50:76–84. DOI: 10.1007/s00535-014-0946-y. PMID: 24603981.

5. Fujiyoshi M, Kuno A, Gotoh M, Fukai M, Yokoo H, Kamachi H, et al. 2015; Clinicopathological characteristics and diagnostic performance of Wisteria floribunda agglutinin positive Mac-2-binding protein as a preoperative serum marker of liver fibrosis in hepatocellular carcinoma. J Gastroenterol. 50:1134–44. DOI: 10.1007/s00535-015-1063-2. PMID: 25773774.

6. Umemura T, Joshita S, Sekiguchi T, Usami Y, Shibata S, Kimura T, et al. 2015; Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein level predicts liver fibrosis and prognosis in primary biliary cirrhosis. Am J Gastroenterol. 110:857–64. DOI: 10.1038/ajg.2015.118. PMID: 25916223.

7. Nishikawa H, Enomoto H, Iwata Y, Kishino K, Shimono Y, Hasegawa K, et al. 2016; Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein for patients with chronic hepatitis B and C: a comparative study. J Viral Hepat. 23:977–84. DOI: 10.1111/jvh.12575. PMID: 27476460.

8. Jekarl DW, Choi H, Lee S, Kwon JH, Lee SW, Yu H, et al. 2018; Diagnosis of liver fibrosis with Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA-M2BP) among chronic hepatitis B patients. Ann Lab Med. 38:348–54. DOI: 10.3343/alm.2018.38.4.348. PMID: 29611385. PMCID: PMC5895864.

9. Moon HW, Park M, Hur M, Kim H, Choe WH, Yun YM. 2018; Usefulness of enhanced liver fibrosis, glycosylation isomer of Mac-2 binding protein, galectin-3, and soluble suppression of tumorigenicity 2 for assessing liver fibrosis in chronic liver diseases. Ann Lab Med. 38:331–7. DOI: 10.3343/alm.2018.38.4.331. PMID: 29611383. PMCID: PMC5895862.

10. Yamasaki K, Tateyama M, Abiru S, Komori A, Nagaoka S, Saeki A, et al. 2014; Elevated serum levels of Wisteria floribunda agglutinin-positive human Mac-2 binding protein predict the development of hepatocellular carcinoma in hepatitis C patients. Hepatology. 60:1563–70. DOI: 10.1002/hep.27305. PMID: 25042054. PMCID: PMC4278450.

11. Heo JY, Kim SU, Kim BK, Park JY, Kim DY, Ahn SH, et al. 2016; Use of Wisteria floribunda agglutinin-positive human Mac-2 binding protein in assessing risk of hepatocellular carcinoma due to hepatitis B virus. Medicine (Baltimore). 95:e3328. DOI: 10.1097/MD.0000000000003328. PMID: 27057911. PMCID: PMC4998827.

12. Kim SU, Heo JY, Kim BK, Park JY, Kim DY, Han KH, et al. 2017; Wisteria floribunda agglutinin-positive human Mac-2 binding protein predicts the risk of HBV-related liver cancer development. Liver Int. 37:879–87. DOI: 10.1111/liv.13341. PMID: 27973711.

13. Shirabe K, Bekki Y, Gantumur D, Araki K, Ishii N, Kuno A, et al. 2018; Mac-2 binding protein glycan isomer (M2BPGi) is a new serum biomarker for assessing liver fibrosis: more than a biomarker of liver fibrosis. J Gastroenterol. 53:819–26. DOI: 10.1007/s00535-017-1425-z. PMID: 29318378.

14. Li Q, Song J, Huang Y, Li X, Zhuo Q, Li W, et al. 2016; The gamma-glutamyl-transpeptidase to platelet ratio does not show advantages than APRI and Fib-4 in diagnosing significant fibrosis and cirrhosis in patients with chronic hepatitis B: a retrospective cohort study in China. Medicine (Baltimore). 95:e3372. DOI: 10.1097/MD.0000000000003372. PMID: 27100421. PMCID: PMC4845825.

15. Kim SU, Han KH, Ahn SH. 2010; Transient elastography in chronic hepatitis B: an Asian perspective. World J Gastroenterol. 16:5173–80. DOI: 10.3748/wjg.v16.i41.5173. PMID: 21049551. PMCID: PMC2975088.

16. Kuno A, Sato T, Shimazaki H, Unno S, Saitou K, Kiyohara K, et al. 2013; Reconstruction of a robust glycodiagnostic agent supported by multiple lectin-assisted glycan profiling. Proteomics Clin Appl. 7:642–7. DOI: 10.1002/prca.201300010. PMID: 23640794.

17. Munteanu M, Ratziu V, Morra R, Messous D, Imbert-Bismut F, Poynard T. 2008; Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-Fibro-Max experience. J Gastrointestin Liver Dis. 17:187–91.

18. Shin JW and Park NH. 2016; Clinical application of non-invasive diagnostic tests for liver fibrosis. Korean J Gastroenterol. 68:4–9. DOI: 10.4166/kjg.2016.68.1.4. PMID: 27443617.

19. Busch K and Thimme R. 2015; Natural history of chronic hepatitis B virus infection. Med Microbiol Immunol. 204:5–10. DOI: 10.1007/s00430-014-0369-7. PMID: 25540037.

20. Wei B, Feng S, Chen E, Li D, Wang T, Gou Y, et al. 2018; M2BPGi as a potential diagnostic tool of cirrhosis in Chinese patients with hepatitis B virus infection. J Clin Lab Anal. 32:e22261. DOI: 10.1002/jcla.22261. PMID: 28544156. PMCID: PMC6817288.

21. Ishii A, Nishikawa H, Enomoto H, Iwata Y, Kishino K, Shimono Y, et al. 2017; Clinical implications of serum Wisteria floribunda agglutinin-positive Mac-2-binding protein in treatment-naïve chronic hepatitis B. Hepatol Res. 47:204–15. DOI: 10.1111/hepr.12703. PMID: 26990490.

22. Mak LY, Wong DK, Cheung KS, Seto WK, Lai CL, Yuen MF. 2018; Role of serum M2BPGi levels on diagnosing significant liver fibrosis and cirrhosis in treated patients with chronic hepatitis B virus infection. Clin Transl Gastroenterol. 9:163. DOI: 10.1038/s41424-018-0020-9. PMID: 29915243. PMCID: PMC6006340.

23. Xu H, Kong W, Liu L, Chi X, Wang X, Wu R, et al. 2017; Accuracy of M2BPGi, compared with Fibro Scan^®, in analysis of liver fibrosis in patients with hepatitis C. BMC Gastroenterol. 17:62. DOI: 10.1186/s12876-017-0618-5. PMID: 28486931. PMCID: PMC5424376.

24. Nakamura M, Kanda T, Jiang X, Haga Y, Takahashi K, Wu S, et al. 2017; Serum microRNA-122 and Wisteria floribunda agglutinin-positive Mac-2 binding protein are useful tools for liquid biopsy of the patients with hepatitis B virus and advanced liver fibrosis. PLoS One. 12:e0177302. DOI: 10.1371/journal.pone.0177302. PMID: 28475652. PMCID: PMC5419651.